Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2016Journal of Clinical HypertensionOpen Access

Mean differences between baseline and follow-up PAC in the control and intervention arm were +3.3 ng/dL and +0.9 ng/dL, respectively (P=.04).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does vitamin D3 supplementation reduce plasma aldosterone concentration in patients with arterial hypertension and vitamin D insufficiency?

Population

200 patients with arterial hypertension and 25-hydroxyvitamin D [25D] levels <30 ng/mL; mean age 60.1±11.3…

Comparison

Vitamin D3 2800 IU vs Placebo

Design

RCT, randomized, double-blind, placebo-controlled

Authors

MGMartin GrüblerMGMartin GakschKKKatharina Kienreich

Discussion

Loading...

Member takes

Overview

Vitamin D supplementation lowers PAC in hypertensive patients with insufficiency; confirms observational vitamin D-aldosterone interplay in an RCT.

Structured PICO

Does vitamin D3 supplementation reduce plasma aldosterone concentration in patients with arterial hypertension and vitamin D insufficiency?

P
Population
200 patients with arterial hypertension and 25-hydroxyvitamin D [25(OH)D] levels <30 ng/mL (188 completed the trial); mean age 60.1±11.3 years, 47% women.
I
Intervention
Vitamin D3 2800 IU
C
Comparator
Placebo
O
Outcome
Plasma aldosterone concentration (PAC)surrogate

Vitamin D3 supplementation significantly decreases plasma aldosterone concentration in patients with arterial hypertension and vitamin D insufficiency.

Limitations

  • post hoc analysis

Cite This Study

Grübler et al. (2016) studied this question.

synapsesocial.com/papers/6a70aac96ceb2bbd16dff66ahttps://doi.org/10.1111/jch.12825
View Full Paper
Ask AI
Bookmark
Share